Strip alopecia in high-dose VMAT-based stereotactic radiosurgery

Anusheel Munshi, MD, DNB, MNAMS; Biplab Sarkar, DipRP, PhD; Sandeep Vaishya, MS, MCH; Kanika Bansal, DNB; Khushboo Rastogi, MD; Tharmamadhar Ganesh, PhD, DABR; Bidhu Kalyan Mohanti, MD

CASE SUMMARY
Between 2013 and 2019, 298 patients were treated with stereotactic radiation therapy (SRT) and radiosurgery (SRS) techniques in our center. The dose fractionation schedules ranged from 30 Gy in 5 fractions to 30 Gy in 1 fraction. A mixture of centrally and peripherally located lesions was seen among the treated patients. Of these patients, 2 reported alopecia over the beam locus. One patient had been treated for arteriovenous malformation (AVM) with a dose of 25 Gy, and the other had been treated for brain metastasis with a dose of 22.5 Gy, both with single-fraction treatments. All plans were meticulously evaluated before treatment delivery. For the first patient, at the time of treatment planning, the scalp was not contoured and the scalp dose was not optimized, whereas for the second patient, drawing of the scalp and its optimization were carried out. On retrospective analysis of the treatment plans, the scalp was contoured on the first patient and its mean dose was found to be 637 cGy (25.5%) of the prescription dose; for the second patient, this was 593 cGy (26.4%).

The manifestation of alopecia in a conventional 1.8 to 2 Gy per fraction treatment regimen is seen with a dose of at least 25 to 30 Gy.1,2 For single-fraction treatments, the typical dose is 5 to 8 Gy of biologically equivalent dose as per a conventional fractionation regimen.3-5 Analysis of all SRS/SRT patients in our center shows a mean scalp dose of 429.0 ± 344 cGy. In our patient subset, we did not come across any incidence of alopecia in patients who received < 15 Gy in a single fraction.

Our experience points to the increased risk of permanent or temporary alopecia in patients having peripherally located lesions when the delivered dose to the planning target volume (PTV) exceeds 20 Gy. We recommended delineation of the scalp and including it in dose optimization.

METHOD
We started our stereotactic program in 2013 and have presented results in multiple forums.6-12 All patients were treated by a frameless stereotactic technique (SRS or SRT) using volumetric-modulated arc therapy (VMAT) on an Axesse (Elekta, Stockholm, Sweden) linear accelerator with a 4-mm multileaf collimator. Typically, SRS patients in our center shows a mean scalp dose of 429.0 ± 344 cGy. In our patient subset, we did not come across any incidence of alopecia in patients who received < 15 Gy in a single fraction.

Further, to evaluate the dose-effect relationship, a scalp organ at risk (OAR) was drawn. The scalp was drawn on the ipsilateral side in all the axial slices in which the lesion was visible. Furthermore, the scalp was extended manually 3 cm in anterior, posterior, cranial and caudal directions. (This was checked by placing a dummy lateral beam ipsilaterally and seeing the projection of the PTV and the scalp in a digitally reconstructed radiography [DRR] mode). We considered only the

Dr. Munshi is the director of radiation oncology. Dr. Sarkar is a senior medical physicist, Dr. Bansal is an assistant consultant, Dr. Rastogi is a senior resident, Dr. Ganesh is the chief medical physicist, and Dr. Mohanti is a senior consultant, all at Manipal Hospitals, New Delhi, India. Dr. Vaishya is the director of neurosurgery, Fortis Memorial Research Institute, Gurgaon, Haryana, India. Disclosure: The authors have no conflicts of interest to disclose. None of the authors received outside funding for the production of this original manuscript and no part of this article has been previously published elsewhere.
ipsilateral and partial scalp falling in the beam locus for optimization and dose evaluation.

Figure 3 presents the scalp as contoured in our clinic. No contouring guidelines are available for contouring the scalp. For the purpose of this study, the scalp was drawn as tissue between the outermost visible soft tissue (on the outside) and the bone/soft tissue interface on the inner side.

IMAGING FINDINGS

Figures 1 and 2 show an alopecia strip following SRS of the patients along with the dose-volume parameters of the radiation therapy plan. Both patients reported with strip alopecia after 2 months of their radiation therapy treatment. Two-year follow-up for case 1 revealed temporary alopecia with partial hair recovery. Initial evaluation of case 2 indicated permanent alopecia; follow-up data was not available as we lost contact with this patient.

Case 1 (Figure 1) was a 33-year-old man with AVM of the right parieto-occipital region. Digital-subtraction angiography showed a right 2.92 cm occipital nidus with extensive angiomatosus changes. The patient received SRS treatment of 25 Gy in a single fraction.

Case 2 (Figure 2) was a 42-year-old woman with squamous cell carcinoma of the left lung. She received concurrent chemoradiation therapy followed by adjuvant chemotherapy. She developed solitary brain metastasis after a disease-free interval of 4 months, and treatment plans were made for a dose of 22.5 Gy in 1 fraction by SRS.

DIAGNOSIS

Case 1: AVM
Case 2: Brain metastasis
DISCUSSION

Over the years, SRS and SRT have become common practice in managing various benign and malignant brain conditions. The typical therapeutic doses are 12 to 30 Gy in 1 to 5 fractions. It is well-known that radiation therapy to the brain can lead to partial or total alopecia. Several investigators have tried to prevent this by various techniques, with mixed results. As with all patients, the treatment plans involved stringent physics quality assurance testing before treatment to ensure dose accuracy. Both patients had a single lesion located peripherally (close to the skull) and were treated with a single fraction (Table 1). In both cases, extensive alopecia was observed with complete loss of hair in the skull area corresponding to the paths of the treatment arcs. Our records of the 298 patients showed that alopecia was not observed in patients who had a centrally located lesion (e.g., secretory pituitary adenoma cases treated with a single dose of 25 to 30 Gy). Similarly, when the prescription dose was < 15 Gy in a single fraction in both centrally and peripherally located lesions, the incidence of alopecia was not observed. The technique of determining a central vs peripheral tumor has been described in our early studies. The analysis of dose and fractionation regimen as a function of dose/fraction ≥ 15 Gy and dose/fraction < 15 Gy is presented in Table 2. The total number of patients was 298, with 41 patients receiving a dose/fraction ≥ 15 Gy and 257 receiving a dose/fraction < 15 Gy.

Table 1. Patient and Dose Characteristics

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Case 1</th>
<th>Case 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis</td>
<td>AVM right parieto-occipital region</td>
<td>Carcinoma left lung with solitary brain metastasis</td>
</tr>
<tr>
<td>Age</td>
<td>33 years</td>
<td>42 years</td>
</tr>
<tr>
<td>Sex</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>PTV volume</td>
<td>4.352 cc</td>
<td>14.496 cc</td>
</tr>
<tr>
<td>Arc start angle/arc length</td>
<td>190°/200°, 180°/40°, 190°/200°</td>
<td>20°/150°, 180°/40°, 180°/160°</td>
</tr>
<tr>
<td>Arc start stop resultant angle</td>
<td>380°, 360°, 380°</td>
<td>180°, 220°, 180°</td>
</tr>
<tr>
<td>Number of arcs used</td>
<td>2 coplanar partial, 1 noncoplanar</td>
<td>2 coplanar, 1 noncoplanar</td>
</tr>
<tr>
<td>Coplanar beams (Yes/No)</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Prescription dose (PTV)/fraction</td>
<td>25 Gy/1 fraction</td>
<td>22.5 Gy/1 fraction</td>
</tr>
<tr>
<td>PTV dose maximum</td>
<td>2751.4 cGy</td>
<td>2792.9 cGy</td>
</tr>
<tr>
<td>Mean scalp dose</td>
<td>637 cGy (25.5%)</td>
<td>593 cGy (26.4%)</td>
</tr>
<tr>
<td>Smallest distance between facing edges of PTV and scalp</td>
<td>2 cm</td>
<td>1.8 cm</td>
</tr>
</tbody>
</table>

Key: PTV = planning target volume, AVM = arteriovenous malformation

Table 2. Analysis of Dose and Fractionation Regimen

<table>
<thead>
<tr>
<th>Dose/Fraction</th>
<th>Average Prescription Dose (cGy)</th>
<th>Average Number of fractions</th>
<th>Average Dose (cGy)/Fraction</th>
<th>Cumulative Scalp Mean Dose (cGy)</th>
<th>Average Scalp Dose (cGy)/Fraction</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 15 Gy</td>
<td>2053.7 ± 385.9</td>
<td>1 ± 0</td>
<td>2053.7 ± 385.9</td>
<td>335.5 ± 179.3</td>
<td>335.5 ± 179.3</td>
</tr>
<tr>
<td>&lt; 15 Gy</td>
<td>1754.3 ± 697.7</td>
<td>2.5 ± 1.8</td>
<td>918.5 ± 348.2</td>
<td>484.4 ± 406</td>
<td>188.5 ± 196.3</td>
</tr>
</tbody>
</table>

The table shows the average cumulative scalp dose and average scalp dose/fraction for 298 patients, with 41 receiving a dose/fraction ≥ 15 Gy and 257 receiving a dose/fraction < 15 Gy.
patients who received regular follow-up did not present with extensive strip alopecia other than these 2 cases.

After observing alopecia and its patterns, we contoured the partial scalp through which the beam entered with appropriate margins to determine whether any dose-effect relationship existed. The treatment planning data revealed that contoured strips of skull in the alopecia zone received a mean dose of 20% of the prescription dose or less. The method section describes the technique of scalp drawing and its dose optimization. We drew a partial scalp since drawing a full scalp seems relatively ineffective in reducing dose to the relevant scalp area. The corresponding average absolute dose to the scalp was approximately 4 to 6 Gy for both patients. It is possible that actual surface doses were slightly different than doses estimated by the treatment planning system (TPS), but they are unlikely to be significantly higher. We did not perform in vivo dosimetry in our patients to confirm the TPS-estimated doses.

The phenomenon of alopecia observed in our cases is intriguing and surprising. VMAT arc-based treatment is an efficient technique of delivering treatment in a short span, causing the least patient discomfort. We used 2 non-coplanar arcs with large arc lengths, mainly aimed at increasing conformity and decreasing scalp dose. Despite these efforts, alopecia occurred. Our experience shows that one must be careful while treating peripherally located brain lesions with an SRS dose exceeding 20 Gy using a double-arc VMAT technique since there is an increased likelihood of hair loss even with the most meticulous planning and dose constraints to the scalp. The resultant alopecia is not patchy but continuous in nature and follows the VMAT arc pattern. A possible suggestion to avoid this strip alopecia is to use multiple smaller fields or to use a full arc (360 degrees) at the time of treatment planning. However, a standard solution for avoiding alopecia is not yet available.

**CONCLUSION**

We present two atypical cases of alopecia in patients treated with VMAT-based, single-fraction SRS for peripherally located tumors. All precautions should be taken to avoid alopecia for hypofractionated treatment—especially cranial stereotaxy—to avoid cosmetic disfigurement. Further study is required to establish the causal relationship between alopecia and dose/delivery technique.

**REFERENCES**
